Position dérivée des transactions déclarées les plus récentes. Non ajustée des splits ni des conversions de classes d'actions.
| Émetteur | Actions | Source | Dernière tx | Détail |
|---|---|---|---|---|
| Decibel Therapeutics, Inc. | 20 000 | déclaré | 11 févr. 2021 | tx 1+20 000 |
| PRUDENTIAL FINANCIAL INC | 11 583 | déclaré | 12 mai 2026 | tx 240+76 249,48−45 367 |
| SHERWIN WILLIAMS CO | 2 573,38 | déclaré | 04 avr. 2025 | tx 57+6 802,12 |
| NEUROCRINE BIOSCIENCES INC | 2 567 | déclaré | 27 mai 2026 | tx 9+31 430−4 753 |
| REGENERON PHARMACEUTICALS, INC. | 1 962 | déclaré | 02 janv. 2026 | tx 86+245 162−202 753 |
| JOHNSON & JOHNSON | 0 | déclaré | 13 févr. 2009 | tx 44+835 947−23 372 |
| Date | Type | Émetteur | Quantité | Prix | Signaux |
|---|---|---|---|---|---|
| 27 mai 2026 | GRANT_AWARD | NEUROCRINE BIOSCIENCES INC | 2 567 | 0.00 USD | deriv |
| 21 mai 2026 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 3 318 | 0.00 USD | |
| 21 mai 2026 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 3 318 | 0.00 USD | deriv |
| 12 mai 2026 | EXERCISE | PRUDENTIAL FINANCIAL INC | 1 765 | 0.00 USD | |
| 12 mai 2026 | OTHER | PRUDENTIAL FINANCIAL INC | 1 765 | 102.58 USD | |
| 12 mai 2026 | GRANT_AWARD | PRUDENTIAL FINANCIAL INC | 1 754 | 0.00 USD | deriv |
| 12 mai 2026 | EXERCISE | PRUDENTIAL FINANCIAL INC | 1 765 | 0.00 USD | deriv |
| 12 mars 2026 | GRANT_AWARD | PRUDENTIAL FINANCIAL INC | 61 | 92.34 USD | deriv |
| 12 mars 2026 | GRANT_AWARD | PRUDENTIAL FINANCIAL INC | 26 | 92.34 USD | deriv |
| 12 mars 2026 | GRANT_AWARD | PRUDENTIAL FINANCIAL INC | 201 | 92.34 USD | deriv |
| 02 janv. 2026 | GRANT_AWARD | REGENERON PHARMACEUTICALS, INC. | 155 | 0.00 USD | |
| 02 janv. 2026 | GRANT_AWARD | REGENERON PHARMACEUTICALS, INC. | 1 962 | 0.00 USD | deriv |
| 11 déc. 2025 | GRANT_AWARD | PRUDENTIAL FINANCIAL INC | 151 | 117.05 USD | deriv |
| 11 déc. 2025 | GRANT_AWARD | PRUDENTIAL FINANCIAL INC | 46 | 117.05 USD | deriv |
| 11 déc. 2025 | GRANT_AWARD | PRUDENTIAL FINANCIAL INC | 19 | 117.05 USD | deriv |
| 29 oct. 2025 | SALE | REGENERON PHARMACEUTICALS, INC. | 1 915 | 654.42 USD | |
| 29 oct. 2025 | SALE | REGENERON PHARMACEUTICALS, INC. | 2 735 | 653.50 USD | |
| 29 oct. 2025 | SALE | REGENERON PHARMACEUTICALS, INC. | 650 | 652.68 USD | |
| 29 oct. 2025 | SALE | REGENERON PHARMACEUTICALS, INC. | 388 | 657.29 USD | |
| 30 oct. 2025 | EXERCISE | REGENERON PHARMACEUTICALS, INC. | 2 712 | 520.01 USD | |
| 29 oct. 2025 | SALE | REGENERON PHARMACEUTICALS, INC. | 712 | 656.50 USD | |
| 29 oct. 2025 | EXERCISE | REGENERON PHARMACEUTICALS, INC. | 6 500 | 520.01 USD | |
| 29 oct. 2025 | SALE | REGENERON PHARMACEUTICALS, INC. | 100 | 655.10 USD | |
| 30 oct. 2025 | EXERCISE | REGENERON PHARMACEUTICALS, INC. | 2 712 | 0.00 USD | deriv |
| 29 oct. 2025 | EXERCISE | REGENERON PHARMACEUTICALS, INC. | 6 500 | 0.00 USD | deriv |
1 achat déclaré après au moins 12 mois de silence — dernière occurrence le 21 mai 2014.